Dr. Joshua Meeks, MD

• Urology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Memorial Sloan-kettering Cancer Center

  Fellowship Hospital, 2012

• Mcgaw Medical Center Of Northwestern University

  Residency Hospital, 2011

• Northwestern University Feinberg School Of Medicine

  Medical School, 2005

• Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer, 2023-04-27

• Scanometric microRNA (Scano-miR) Array Profiling of Prostate Cancer Markers Using Spherical Nucleic Acid (SNA)-Gold Nanoparticle Conjugates, 2012-04-10

• Common Variants in 8q24 and MYC Oncogene are Associated with Risk for Prostate Cancer and Tumor Aggressiveness in Men of European Ancestry, 2009-10-01

• Genetic Prostate Cancer Risk Assessment: Common Variants in 9 Genomic Regions are Associated with Cumulative Risk, 2010-06-17

• APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response, 2017-12-16

• Development of a Translational Medicine Protocol for an NCTN Genitourinary Clinical Trial: Critical Steps, Common Pitfalls and a Basic Guide to Translational Clinical Research, 2018-08-13

• The Emerging Role of Homologous Recombination Repair and PARP Inhibitors in Genitourinary Malignancies, 2017-03-21

• Pathologic Outcomes Associated with the 17q Prostate Cancer Risk Variants, 2009-04-16

• Characteristics of Prostate Cancers Detected at Prostate-Specific Antigen Levels Less than 2.5 ng/ml, 2009-04-16

• The Evolving Management of Patients with Clinical Stage I Seminoma, 2016-08-12

• MutSignatures: an R package for extraction and analysis of cancer mutational signatures, 2020-10-26

• Reply by the Authors, 2017-08-25

• A Carcinogen-induced Mouse Model Recapitulates the Molecular Alterations of Human Muscle Invasive Bladder Cancer, 2018-01-25

• Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer, 2021-04-15

• An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer, 2021-04-16

• A simplified nomogram to assess risk of bladder cancer in patients with a new diagnosis of microscopic hematuria, 2020-01-14

• Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy, 2022-08-18

• Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen, 2018-02-02

• Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies, 2020-06-16

• First in Human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in BCG-Unresponsive Bladder Cancer, 2022-08-23

• ?d T cells support antigen-specific aß T cell-mediated antitumor responses during BCG treatment for bladder cancer, 2021-10-04

• Frequency of Testing for Prostate Cancer Using Prostate-Specific Antigen among Older Men in a Large Health System, 2018-11-17

• Genomic characterization of high-risk non-muscle invasive bladder cancer, 2016-10-14

• Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes, 2020-03-31

• Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy, 2016-02-22